OptiNose Inc
OPTN
Company Profile
Business description
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Contact
1020 Stony Hill Road
Suite 300
YardleyPA19067
USAT: +1 267 364-3500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
132
Stocks News & Analysis
stocks
Megatrend Investing 2025 and beyond: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
stocks
DeepSeek revelation hits US chip stocks, ASX data centres and uranium
Shockwaves from Monday's AI stock panic in the US were largely confined to two ASX industries.
video
What does a weak Aussie dollar mean for investors?
Morningstar Investment Management's Chief Investment Officer for Asia Pacific weighs in on the weak Aussie dollar and what this could mean for investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,789.70 | 43.80 | 0.50% |
| CAC 40 | 7,950.17 | 8.53 | 0.11% |
| DAX 40 | 21,732.05 | 4.85 | 0.02% |
| Dow JONES (US) | 44,544.66 | 337.47 | -0.75% |
| FTSE 100 | 8,673.96 | 27.08 | 0.31% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,627.44 | 54.31 | -0.28% |
| Nikkei 225 | 39,572.49 | 58.52 | 0.15% |
| NZX 50 Index | 12,995.01 | 66.63 | 0.52% |
| S&P 500 | 6,040.53 | 30.64 | -0.50% |
| S&P/ASX 200 | 8,532.30 | 38.60 | 0.45% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |